πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to AlloVir, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Alector, Inc.

Alector, Inc. logo
Market Cap: Medium
Employees: Low

AL001, AL101, AL002, AL003, AL044

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.

Tags: Alzheimer's, Parkinson's, biopharmaceutical, clinical trials, neurodegeneration, therapies

Symbol: ALEC

Recent Price: $1.72

Industry: Biotechnology

CEO: Dr. Arnon Rosenthal Ph.D.

Sector: Healthcare

Employees: 245

Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 415 231 5660

Leadership

  • Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
  • Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
  • Marc Grasso, M.D., Chief Financial Officer
  • Gary Romano, M.D., Ph.D., Chief Medical Officer
  • Danielle Pasqualone, Ph.D., J.D., General Counsel
  • Clare Hunt, M.B.A., Chief People Officer
  • Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
  • Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
  • Norah Conway, Senior Vice President, Portfolio and Program Management
  • Neil Berkley, M.S., M.B.A., Chief Business Officer
  • Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
  • Elizabeth Garofalo, M.D., Board Member
  • Paula Hammond, Ph.D., Board Member
  • Richard H. Scheller, Ph.D., Board Member
  • David Wehner, Board Member
  • Kristine Yaffe, M.D., Board Member
  • Errol De Souza, Ph.D., Board Member
  • Mark Altmeyer, M.B.A., Board Member

Last updated: 2024-12-31

Genelux Corporation

Genelux Corporation logo
Market Cap: Low
Employees: Lowest

Olvi-Vec

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for tough-to-treat cancers, with a lead product candidate, Olvi-Vec.

Tags: Olvi-Vec, biopharmaceutical, cancer treatment, clinical-stage, oncolytic viral immunotherapies

Symbol: GNLX

Recent Price: $2.40

Industry: Biotechnology

CEO: Mr. Thomas Zindrick J.D.

Sector: Healthcare

Employees: 24

Address: 2625 Townsgate Road, Westlake Village, CA 91361

Phone: 858 483 0024

Leadership

  • Bob Smith, CTO
  • THOMAS ZINDRICK, J.D., Chairman
  • JAMES L. TYREE, MBA, Lead Independent Director
  • MARY MIRABELLI, MBA, Chair, Nominating and Corporate Governance Committee
  • JOHN THOMAS, M.A., MBA, Ph.D., Chair, Audit Committee
  • JOHN SMITHER, Chair, Compensation Committee
  • Alice Johnson, CEO
  • Carol Davis, CFO
  • David Wilson, Chairman
  • Eva Brown, Director

Last updated: 2024-12-31

Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

TELOMIR-1

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on developing and commercializing therapies for age-related inflammatory conditions and post-chemotherapy recovery.

Tags: TELOMIR-1, inflammatory conditions, pharmaceutical, stem cells, therapeutic treatment

Symbol: TELO

Recent Price: $4.64

Industry: Biotechnology

CEO: Mr. Erez Aminov

Sector: Healthcare

Employees: 1

Address: 855 N Wolfe Street, Baltimore, null 21205

Phone: (737)-289-0835

Last updated: 2024-12-31

Arcellx, Inc.

Arcellx, Inc. logo
Market Cap: High
Employees: Low

CART-dd BCMA

Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.

Tags: acute myeloid leukemia, biotechnology, cancer treatment, clinical-stage, immunotherapy, multiple myeloma, myelodysplastic syndrome

Symbol: ACLX

Recent Price: $78.35

Industry: Biotechnology

CEO: Mr. Rami Elghandour

Sector: Healthcare

Employees: 130

Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878

Phone: 240 327 0603

Last updated: 2024-12-31

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

UCART19

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Tags: CAR T cell, allogeneic T cell therapies, cancer treatment, clinical trials, immuno-oncology

Symbol: ALLO

Recent Price: $2.10

Industry: Biotechnology

CEO: Dr. David D. Chang M.D., Ph.D.

Sector: Healthcare

Employees: 232

Address: 210 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 457 2700

Last updated: 2024-12-31

Altimmune, Inc.

Altimmune, Inc. logo
Market Cap: Medium
Employees: Lowest

Pemvidutide

Altimmune, Inc. focuses on developing treatments for obesity and liver diseases with lead product candidate pemvidutide, and Hep Tcell in clinical trials.

Tags: Phase 1b trial, Phase 2 trial, biopharmaceutical, hepatic, liver diseases, obesity

Symbol: ALT

Recent Price: $7.32

Industry: Biotechnology

CEO: Dr. Vipin K. Garg Ph.D.

Sector: Healthcare

Employees: 59

Address: 910 Clopper Road, Gaithersburg, MD 20878

Phone: 240 654 1450

Last updated: 2024-12-31

AlloVir, Inc.

AlloVir, Inc. logo
Market Cap: Low
Employees: Lowest

posoleucel

Allovir, Inc. is a clinical-stage cell therapy company focused on the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat viral-associated diseases. It was founded in 2013 and is based in Waltham, Massachusetts.

Tags: VST therapies, biotechnology, cell therapy, clinical-stage, viral diseases

Symbol: ALVR

Recent Price: $0.45

Industry: Biotechnology

CEO: Dr. Diana M. Brainard M.D.

Sector: Healthcare

Employees: 8

Address: 1100 Winter Street, Waltham, MA 02451

Phone: 617 433 2605

Last updated: 2024-12-31

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. logo
Market Cap: Low
Employees: Low

ALX148

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies for cancer patients. Its lead product, ALX148, targets CD47 and is in trials for various cancers. The company also explores pre-clinical treatments like ALTA-002 to enhance immune response to cancer.

Tags: CD47, cancer therapy, clinical trials, collaboration, immuno-oncology, solid tumors

Symbol: ALXO

Recent Price: $1.66

Industry: Biotechnology

CEO: Mr. Jason W. Lettmann

Sector: Healthcare

Employees: 81

Address: 323 Allerton Avenue, South San Francisco, CA 94080

Phone: 650 466 7125

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

GeoVax Labs, Inc.

GeoVax Labs, Inc. logo
Market Cap: Lowest
Employees: Lowest

Modified Vaccinia Ankara Virus-Like Particle Vaccine Platform

Geo Vax Labs, Inc. develops human vaccines and immunotherapies against infectious diseases and cancers using its proprietary modified vaccinia ankara virus-like particle vaccine platform. The company focuses on preventive vaccines for diseases like COVID-19, HIV, Zika, malaria, and hemorrhagic fever viruses, as well as therapeutic vaccines for HIV and chronic Hepatitis B.

Tags: biotechnology, cancer, immunotherapy, infectious diseases, vaccines

Symbol: GOVX

Recent Price: $2.44

Industry: Biotechnology

CEO: Mr. David Alan Dodd

Sector: Healthcare

Employees: 17

Address: 1900 Lake Park Drive, Smyrna, GA 30080

Phone: 678 384 7220

Last updated: 2024-12-31

HilleVax, Inc.

HilleVax, Inc. logo
Market Cap: Low
Employees: Low

HIL-214

Hille Vax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines, including HIL-214, for the prevention of norovirus infection.

Tags: biopharmaceutical, clinical-stage, norovirus, vaccines

Symbol: HLVX

Recent Price: $1.98

Industry: Biotechnology

CEO: Dr. Robert M. Hershberg M.D., Ph.D.

Sector: Healthcare

Employees: 90

Address: 75 State Street, Boston, MA 02109

Phone: 617 213 5054

Last updated: 2024-12-31

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. logo
Market Cap: High
Employees: Medium

lifileucel

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to utilize the immune system in eradicating cancer cells, with several ongoing phase 2 clinical studies.

Tags: biotechnology, cancer immunotherapy, cancer treatment, clinical-stage, lifileucel

Symbol: IOVA

Recent Price: $7.17

Industry: Biotechnology

CEO: Dr. Frederick G. Vogt Esq., J.D., Ph.D.

Sector: Healthcare

Employees: 557

Address: 825 Industrial Road, San Carlos, CA 94070

Phone: 650 260 7120

Last updated: 2024-12-31

Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Adoptive TCR Engineered T-cell Therapies

Alaunos Therapeutics is a clinical-stage company focused on developing cell therapies for cancer treatment, utilizing TCR engineered T-cell therapies in clinical trials for various cancers.

Tags: TCR Library, biotechnology, cancer treatment, cell therapy, clinical trials, oncology

Symbol: TCRT

Recent Price: $2.17

Industry: Biotechnology

CEO: Mr. Dale Curtis Hogue Jr.

Sector: Healthcare

Employees: 1

Address: 8030 El Rio Street, Houston, TX 77054

Phone: 346 355 4099

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Vor Biopharma Inc.

Vor Biopharma Inc. logo
Market Cap: Lowest
Employees: Low

VOR33

Vor Biopharma, Inc. is a clinical-stage company focused on developing engineered hematopoietic stem cell (e HSC) therapies for cancer patients, with a leading product, VOR33, in phase 1/2 trials for AML and other hematological malignancies.

Tags: AML, biotechnology, cancer therapies, e HSC, hematopoietic stem cells

Symbol: VOR

Recent Price: $1.19

Industry: Biotechnology

CEO: Dr. Robert Ang M.B.A., M.D., MBBS

Sector: Healthcare

Employees: 168

Address: 100 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 655 6580

Leadership

  • Robert Ang, MBBS, MBA, President and Chief Executive Officer
  • Eyal Attar, MD, Chief Medical Officer
  • Tirtha Chakraborty, PhD, Chief Scientific Officer
  • Han Choi, MD, LLM, Chief Financial Officer
  • John King, MBA, Chief Commercial Officer and Head of Business Development
  • Tania Philipp, Chief People Officer
  • David Phillips, MBA, Senior Vice President, Head of Quality
  • Samir Vattompadam, MS, Senior Vice President, Portfolio Strategy and Program Management
  • Daniella Beckman, Board of Directors
  • David Lubner, Board of Directors
  • Bill Lundberg, MD, Board of Directors
  • Fouad Namouni, MD, Board Of Directors
  • Matthew R. Patterson, Chairman, Board of Directors
  • Josh Resnick, MD, Board of Directors

Last updated: 2024-12-31

Vaxart, Inc.

Vaxart, Inc. logo
Market Cap: Low
Employees: Low

Oral Recombinant Protein Vaccines

Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines using a proprietary oral vaccine platform. Their product pipeline includes vaccines for norovirus, seasonal influenza, respiratory syncytial virus, and coronavirus, along with therapeutic vaccines for cervical cancer and dysplasia.

Tags: HPV, RSV, biotechnology, cervical cancer, coronavirus, influenza, norovirus, oral vaccines

Symbol: VXRT

Recent Price: $0.69

Industry: Biotechnology

CEO: Mr. Steven Lo

Sector: Healthcare

Employees: 109

Address: 170 Harbor Way, South San Francisco, CA 94080

Phone: 650 550 3500

Last updated: 2024-12-31

Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

ALG-010133

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for viral and liver diseases, with a focus on chronic hepatitis B and non-alcoholic steatohepatitis.

Tags: NASH, biopharmaceutical, chronic hepatitis B, liver diseases, therapeutics

Symbol: ALGS

Recent Price: $40.47

Industry: Biotechnology

CEO: Dr. Lawrence M. Blatt MBA, Ph.D.

Sector: Healthcare

Employees: 68

Address: One Corporate Drive, South San Francisco, CA 94080

Phone: 800 466 6059

Last updated: 2024-12-31

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. logo
Market Cap: Lowest
Employees: Lowest

APVO436

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of immunotherapeutic candidates to treat various forms of cancer, with a primary focus on APVO436, a bispecific T-cell engaging antibody for leukemia and myelodysplastic syndrome.

Tags: biotechnology, bispecific antibodies, cancer treatment, clinical-stage, immunotherapy

Symbol: APVO

Recent Price: $4.78

Industry: Biotechnology

CEO: Mr. Marvin L. White

Sector: Healthcare

Employees: 40

Address: 2401 4th Avenue, Seattle, WA 98121

Phone: 206 838 0500

Leadership

  • Marvin L. White, President and Chief Executive Officer
  • Jeff Lamothe, EVP and Chief Operating Officer
  • Daphne Taylor, SVP and Chief Financial Officer
  • Dirk Huebner, M.D., Chief Medical Officer
  • SoYoung Kwon, SVP, General Counsel, Business Development and Corporate Affairs

Last updated: 2024-12-31